The DOI matches its Crossref record; 105 of the 105 references it cites were found in a registry or an index.
Overcoming cellular barriers for RNA therapeutics
Abstract
RNA-based therapeutics, such as small-interfering (siRNAs), microRNAs (miRNAs), antisense oligonucleotides (ASOs), aptamers, synthetic mRNAs and CRISPR-Cas9, have great potential to target a large part of the currently undruggable genes and gene products and to generate entirely new therapeutic paradigms in disease, ranging from cancer to pandemic influenza to Alzheimer's disease. However, for these RNA modalities to reach their full potential, they first need to overcome a billion years of evolutionary defenses that have kept RNAs on the outside of cells from invading the inside of cells. Overcoming the lipid bilayer to deliver RNA into cells has remained the major problem to solve for widespread development of RNA therapeutics, but recent chemistry advances have begun to penetrate this evolutionary armor.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“As an emerging programmable gene interference technique, siRNA offers high specificity and flexibility in targeting the diseased human genome [236].”
From Emerging role of exosomes in cancer therapy: progress and challenges (2025) · cites this paper as [236]
In the citing paper
“Many obstacles still exist despite the rise in studies on delivery platforms, including toxicity and the precise distribution of mRNA to extrahepatic organs [13, 14].”
From Exosome for mRNA delivery: Strategies and therapeutic applications (2024) · cites this paper as [13]
In the citing paper
“Independent of the administration route, several evolutionary barriers are designed to prevent any intrusion of foreign nucleic acids and thus limit the delivery of exogenous mRNA [74].”
From Three decades of messenger RNA vaccine development (2019) · cites this paper as [74]
In the citing paper
“For instance, RNA interference (RNAi) technology enables the downregulation of disease related genes and protein expression; mRNA mediates the expression and supplementation of therapeutic proteins; the CRISPR gene editing system facilitates gene engineering in vivo or through cell engineering ex vivo.[6, 9, 11, 17–20]”
From RNA delivery biomaterials for the treatment of genetic and rare diseases (2019) · cites this paper as [19]
In the citing paper
“For instance, RNA interference (RNAi) technology enables the downregulation of disease related genes and protein expression; mRNA mediates the expression and supplementation of therapeutic proteins; the CRISPR gene editing system facilitates gene engineering in vivo or through cell engineering ex vivo.[6, 9, 11, 17–20]”
From RNA delivery biomaterials for the treatment of genetic and rare diseases (2019) · cites this paper as [19]
In the citing paper
“For instance, RNA interference (RNAi) technology enables the downregulation of disease related genes and protein expression; mRNA mediates the expression and supplementation of therapeutic proteins; the CRISPR gene editing system facilitates gene engineering in vivo or through cell engineering ex vivo.[6, 9, 11, 17–20]”
From RNA delivery biomaterials for the treatment of genetic and rare diseases (2019) · cites this paper as [19]
In the citing paper
“With the development of chemical modifications on RNA molecules, modified siRNA are reported to remain intact for long durations under circulation, which provides the possibility of delivering siRNA without the shielding of nanoparticles.[19, 75, 76]”
From RNA delivery biomaterials for the treatment of genetic and rare diseases (2019) · cites this paper as [19]
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116
Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans
Fire, A., Xu, S., Montgomery, M. K., Kostas, S. A., Driver, S. E., & Mello, C. C. (1998) · Nature · doi:10.1038/35888 · Cited by 15,429
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells
Elbashir, S. M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K., & Tuschl, T. (2001) · Nature · doi:10.1038/35078107 · Cited by 9,456
RNA-Guided Human Genome Engineering via Cas9
Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., & Church, G. M. (2013) · Science · doi:10.1126/science.1232033 · Cited by 9,210
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Direct Gene Transfer into Mouse Muscle in Vivo
Wolff, J. A., Malone, R. W., Williams, P., Chong, W., Acsadi, G., Jani, A., & Felgner, P. L. (1990) · Science · doi:10.1126/science.1690918 · Cited by 4,173
Doherty, G. J., & McMahon, H. T. (2009) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.78.081307.110540 · Cited by 3,075
In vivo genome editing using Staphylococcus aureus Cas9
Ran, F. A., Cong, L., Yan, W. X., Scott, D. A., Gootenberg, J. S., Kriz, A. J., Zetsche, B., Shalem, O., Wu, X., Makarova, K. S., et al. (2015) · Nature · doi:10.1038/nature14299 · Cited by 2,687
Flagged first, then by citations
Research works printed but not linked: 2
- Rich, A. in Horizons In Biochemistry (eds. Kasha, M. & Pullman, B.) 103–126 (Academic Press, New York, 1962).
- Cummings, R. & McEver, R. in Essentials of Glycobiology. 2nd edn. (eds. Varki, A. et al.) Chapter 31 (Cold Spring Harbor (NY); Cold Spring Harbor Laboratory Press, 2009).
Cited by
Sorted by citations
Items 601–700 of 1,000
Vasconcelos, D., Lehto, T., Madani, F., Radoi, V., Hällbrink, M., Vukojević, V. B., & Langel, Ü. (2017) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2017.09.024 · Cited by 16
Xie, Y., Wang, Y., Li, J., Yu, H., & Oupický, D. (2018) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1528 · Cited by 17
Liu, J., Cai, B., Cui, L., & Chen, C. (2020) · Science China Materials · doi:10.1007/s40843-020-1296-8 · Cited by 16
Viral Mimicry as a Design Template for Nucleic Acid Nanocarriers
de la Fuente, I. F., Sawant, S. S., Tolentino, M. Q., Corrigan, P. M., & Rouge, J. L. (2021) · Frontiers in Chemistry · doi:10.3389/fchem.2021.613209 · Cited by 17
In Vitro Evaluation of a Nanoparticle-Based mRNA Delivery System for Cells in the Joint
Sturm, L., Faustini, B., Menzel, U., Häckel, S., Albers, C. E., Plank, C., Rip, J., Alini, M., Traweger, A., Grad, S., et al. (2021) · Biomedicines · doi:10.3390/biomedicines9070794 · Cited by 16
Engineering CRISPR-Cas9 RNA–Protein Complexes for Improved Function and Delivery
Rouet, R., de Oñate, L., Li, J., Murthy, N., & Wilson, R. C. (2018) · The CRISPR Journal · doi:10.1089/crispr.2018.0037 · Cited by 16
Lorenzer, C., Streußnig, S., Tot, E., Winkler, A.-M., Merten, H., Brandl, F., Sayers, E. J., Watson, P., Jones, A. T., Zangemeister‐Wittke, U., et al. (2019) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2019.05.015 · Cited by 16
Taniguchi, H., Suzuki, Y., Imai, K., & Adachi, Y. (2022) · Cancer Science · doi:10.1111/cas.15461 · Cited by 15
Heterogeneous Nanostructures Cause Anomalous Diffusion in Lipid Monolayers
Liu, Y., Zheng, X., Guan, D., Jiang, X., & Hu, G. (2022) · ACS Nano · doi:10.1021/acsnano.2c04089 · Cited by 15
Lou, Y., Wang, Y., Lu, J. J., & Chen, X. (2025) · Nanomedicine · doi:10.1080/17435889.2025.2492542 · Cited by 19
Rasale, D. B., Patil, K. M., Sauter, B., Geigle, S. N., Zhanybekova, S., & Gillingham, D. G. (2018) · Chemical Communications · doi:10.1039/c8cc04476g · Cited by 15
RNA Engineering for Public Health: Innovations in RNA-Based Diagnostics and Therapeutics
Thavarajah, W., Hertz, L. M., Bushhouse, D. Z., Archuleta, C. M., & Lucks, J. B. (2021) · Annual Review of Chemical and Biomolecular Engineering · doi:10.1146/annurev-chembioeng-101420-014055 · Cited by 15
Zhao, Q., Zhang, K., Li, Y., Ren, Y., Shi, J., Gu, Y., Qiu, S., Liu, S., Cheng, Y., Qiao, Y., et al. (2021) · Translational Oncology · doi:10.1016/j.tranon.2021.101100 · Cited by 15
Johannes, L. (2021) · Molecules · doi:10.3390/molecules26113299 · Cited by 16
Hiraoka, H., Shu, Z., Le, B. T., Masuda, K., Nakamoto, K., Lyu, F., Abe, N., Hashiya, F., Kimura, Y., Shimizu, Y., et al. (2021) · ChemBioChem · doi:10.1002/cbic.202100413 · Cited by 15
Swevers, L., Kontogiannatos, D., Κολλιοπούλου, Ά., Ren, F., Feng, M., & Sun, J. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.749387 · Cited by 15
Yong, X., Yang, X., Emory, S. R., Wang, J., Dai, J., Yu, X., Mei, L., Xie, J., & Ruan, G. (2018) · Biomaterials Science · doi:10.1039/c8bm00928g · Cited by 15
Tips for Successful lncRNA Knockdown Using Gapmers
Lennox, K. A., & Behlke, M. A. (2020) · Methods in molecular biology · doi:10.1007/978-1-0716-0771-8_9 · Cited by 15
Light-triggered nanocarriers for nucleic acid delivery
Huang, B., Smedt, S. C. D., Vos, W. H. D., & Braeckmans, K. (2025) · Drug Delivery · doi:10.1080/10717544.2025.2502346 · Cited by 14
Wu, Q.-X., de Isla, N., & Zhang, L. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26157384 · Cited by 15
Shi, S. Y., Luo, X., Yamawaki, T., Li, C.-M., Ason, B. L., & Furtado, M. B. (2021) · Current Cardiology Reports · doi:10.1007/s11886-021-01517-z · Cited by 14
Aptamer Technology and Its Applications in Bone Diseases
Liu, X., Hu, J., Ning, Y., Xu, H., Cai, H., Yang, A., Shi, Z.-S., & Li, Z. (2023) · Cell Transplantation · doi:10.1177/09636897221144949 · Cited by 16
Recent Advances in Messenger Ribonucleic Acid (mRNA) Vaccines and Their Delivery Systems: A Review
Belay, W. Y., Nibret, G., & Aschale, Y. (2023) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s418314 · Cited by 16
Exploration of mRNA nanoparticles based on DOTAP through optimization of the helper lipids
Ma, X., Wu, F., Peng, C., Chen, H., Zhang, D., & Han, T. (2023) · Biotechnology Journal · doi:10.1002/biot.202300123 · Cited by 16
Novel Lipid Nanoparticles Stable and Efficient for mRNA Transfection to Antigen-Presenting Cells
Choi, K. C., Lee, D. H., Lee, J., Lee, J. S., Lee, Y. K., Choi, M. J., Jeong, H. Y., Kim, M. W., Lee, C.-G., & Park, Y. S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031388 · Cited by 14
Waghode, P., Quadir, S. S., Choudhary, D. K., Sharma, S., & Joshi, G. (2024) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-024-01405-7 · Cited by 14
A journey into siRNA therapeutics development: A focus on Pharmacokinetics and Pharmacodynamics
Choi, G.-W., Kim, J. H., Kang, D. W., & Cho, H. (2024) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2024.106981 · Cited by 18
Sghyar, R., Lahyaoui, M., Rhazi, Y., Aflak, N., Moussaoui, O., Chda, A., Alanazi, M. M., Kabra, A., Hadrami, E. M. E., Mabrouk, E. H., et al. (2025) · ACS Omega · doi:10.1021/acsomega.4c08773 · Cited by 14
Poly-lysine-modified recombinant protein nanocages for effective delivery of small activating RNA
Xu, L., Li, S., Wan, S., Liu, Z., Zhong, Y., Qian, X., Qin, J., Cai, L., & Huang, H. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113638 · Cited by 14
AATF/Che-1—An RNA Binding Protein at the Nexus of DNA Damage Response and Ribosome Biogenesis
Kaiser, R. W. J., Erber, J., Höpker, K., Fabretti, F., & Müller, R. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00919 · Cited by 13
Conjugation of Oligonucleotides to Peptide Aldehydes via a pH-Responsive N-Methoxyoxazolidine Linker
Aho, A., Sulkanen, M., Korhonen, H. J., & Virta, P. (2020) · Organic Letters · doi:10.1021/acs.orglett.0c01815 · Cited by 14
Use of homoarginine to obtain attenuated cationic membrane lytic peptides
Sakamoto, K., Akishiba, M., Iwata, T., Arafiles, J. V. V., Imanishi, M., & Futaki, S. (2021) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2021.127925 · Cited by 14
Advances in liposome-based delivery of RNA therapeutics for cancer treatment
Sanati, M., Afshari, A. R., Ahmadi, S. S., Kesharwani, P., & Sahebkar, A. (2024) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2023.12.010 · Cited by 14
Andersson, P. U., & den Besten, C. (2019) · Royal Society of Chemistry eBooks · doi:10.1039/9781788015714-00474 · Cited by 16
RNA and CRISPR Interferences: Past, Present, and Future Perspectives
Sioud, M. (2020) · Methods in molecular biology · doi:10.1007/978-1-0716-0290-4_1 · Cited by 14
Zou, J., Xia, C., Yao, M., Pan, X., Zheng, S., Lin, Y., Zhao, X., Wang, Y., Chen, Y., Lan, M., et al. (2025) · Chemical Engineering Journal · doi:10.1016/j.cej.2025.161997 · Cited by 13
Advances and Strategies in Enhancing mRNA Cancer Vaccines
Zhang, M., Chen, S., Hu, H.-J., Ong, Y., & Ni, Q. (2025) · Advanced Materials · doi:10.1002/adma.202509880 · Cited by 17
Transcriptomics and RNA-Based Therapeutics as Potential Approaches to Manage SARS-CoV-2 Infection
Arriaga-Canon, C., Contreras‐Espinosa, L., Rebollar‐Vega, R., Montiel-Manríquez, R., Cedro‐Tanda, A., García-Gordillo, J. A., Álvarez-Gómez, R. M., Jiménez-Trejo, F. J., Hernández, C. C., & Herrera, L. A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911058 · Cited by 14
Repositioning the antihistamine ebastine as an intracellular siRNA delivery enhancer
Muntean, C., Blondeel, E., Harinck, L., Pednekar, K. P., Prakash, J., Wever, O. D., Chain, J. L., Smedt, S. C. D., Remaut, K., & Raemdonck, K. (2023) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2023.123348 · Cited by 13
RuizdelRio, J., Guedes, G., Novillo, D., Lecue, E., Palanca, A., Cortajarena, A. L., & Villar, A. V. (2023) · Theranostics · doi:10.7150/thno.85409 · Cited by 13
Parveen, A., & Elkordy, A. (2024) · Pathogens · doi:10.3390/pathogens13060500 · Cited by 13
Implementation of mRNA–Lipid Nanoparticle Technology in Atlantic Salmon (Salmo salar)
Dahl, L. O. S., Hak, S., Braaen, S., Molska, A., Rodà, F., Parot, J., Wessel, Ø., Fosse, J. H., Bjørgen, H., Borgos, S. E., et al. (2024) · Vaccines · doi:10.3390/vaccines12070788 · Cited by 17
Parveen, N., Rimkutė, I., Block, S., Rydell, G. E., Midtvedt, D., Larson, G., Hytönen, V. P., Zhdanov, V. P., Lundgren, A., & Höök, F. (2018) · The Journal of Physical Chemistry Letters · doi:10.1021/acs.jpclett.8b00433 · Cited by 13
Nawale, G. N., Bahadorikhalili, S., Sengupta, P., Kadekar, S., Chatterjee, S., & Varghese, O. P. (2019) · Chemical Communications · doi:10.1039/c9cc04141a · Cited by 13
Molecular regulation of hypoxia through the lenses of noncoding RNAs and epitranscriptome
Islam, S., & Mukherjee, C. (2022) · Wiley Interdisciplinary Reviews - RNA · doi:10.1002/wrna.1750 · Cited by 14
Cancer Stem Cells—The Insight into Non-Coding RNAs
Bryl, R., Piwócka, O., Kawka, E., Mozdziak, P. E., Kempisty, B., & Knopik-Skrocka, A. (2022) · Cells · doi:10.3390/cells11223699 · Cited by 14
Baljon, J. J., Dandy, A., Wang-Bishop, L., Wehbe, M., Jacobson, M. E., & Wilson, J. T. (2019) · Biomaterials Science · doi:10.1039/c9bm90022e · Cited by 13
Maziec, K., Baliga-Gil, A., & Kierzek, E. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102572 · Cited by 15
Noncoding RNA therapeutics for substance use disorder
Seyednejad, S. A., & Sartor, G. C. (2022) · Advances in Drug and Alcohol Research · doi:10.3389/adar.2022.10807 · Cited by 13
Polyphenol‐Based Assembly Nanosystems as Multifunctional Biopharmaceutical Platform
Jiang, X. Y., Zhang, J., Lo, P. K., & Mao, Z. (2023) · Advanced NanoBiomed Research · doi:10.1002/anbr.202200168 · Cited by 12
Chen, W., Ruan, M., Zou, M., Liu, F., & Liu, H. (2023) · Cancers · doi:10.3390/cancers15164187 · Cited by 12
Chatterjee, S., Bhattacharya, M., Lee, S., & Chakraborty, C. (2023) · Current Research in Biotechnology · doi:10.1016/j.crbiot.2023.100150 · Cited by 12
Mahmoudi, A. A., Rostami, M., Hajihasani, M. M., Sukhorukov, V. N., Kesharwani, P., & Sahebkar, A. (2024) · European Polymer Journal · doi:10.1016/j.eurpolymj.2024.112866 · Cited by 12
Non-viral delivery of RNA for therapeutic T cell engineering
Berdecka, D., Smedt, S. C. D., Vos, W. H. D., & Braeckmans, K. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115215 · Cited by 14
Qutub, S., Bhat, I. A., Maatouk, B. I., Moosa, B., Fakim, A., Nawaz, K., Díaz‐Galicia, E., Lin, W., Grünberg, R., Arold, S. T., et al. (2024) · Angewandte Chemie International Edition · doi:10.1002/anie.202403647 · Cited by 12
Silk–gelatin hybrid hydrogel: a potential carrier for RNA therapeutics
Mahaling, B., Roy, C., & Ghosh, S. (2024) · Journal of Materials Chemistry B · doi:10.1039/d4tb00491d · Cited by 12
Current concepts of the crosstalk between lncRNA and E2F1: shedding light on the cancer therapy
Huang, P., Wen, F., & Li, Q. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1432490 · Cited by 12
A review of the complex interplay between chemoresistance and lncRNAs in lung cancer
Alnefaie, G. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05877-2 · Cited by 13
Ribonuclease activity undermines immune sensing of naked extracellular RNA
Castellano, M., Blanco, V., Calzi, M. L., Costa, B., Witwer, K. W., Hill, M., Cayota, A., Segovia, M., & Tosar, J. P. (2025) · Cell Genomics · doi:10.1016/j.xgen.2025.100874 · Cited by 13
The emerging roles of long non-coding RNAs in the nervous system
Altaf, S., Cummins, M. J., Ittner, L. M., & Mattick, J. S. (2025) · Nature reviews. Neuroscience · doi:10.1038/s41583-025-00960-z · Cited by 18
Han, M., Beon, J., Lee, J. Y., & Oh, S. S. (2021) · Macromolecular Research · doi:10.1007/s13233-021-9093-5 · Cited by 12
Long noncoding RNAs induced control of ferroptosis: Implications in cancer progression and treatment
Shi, W., & Sethi, G. (2023) · Journal of Cellular Physiology · doi:10.1002/jcp.30992 · Cited by 13
Plumbing mysterious RNAs in “dark genome” for the conquest of human diseases
Huang, L. A., Lin, C., & Yang, L. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.05.003 · Cited by 12
Addison, M., Ranasinghe, P. D., & Webb, D. J. (2023) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2023.2277330 · Cited by 14
Factors affecting the association of single- and double-stranded RNAs with montmorillonite nanoclays
Gujjari, A., Rodriguez, B. V., Pescador, J., Maeder, C., Beall, G. W., & Lewis, L. K. (2017) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2017.12.124 · Cited by 12
Peng, Z., Li, J., Li, S., Pardo, J., Zhou, Y., Al-Youbi, A. O., Bashammakh, A. S., El-Shahawi, M. S., & Leblanc, R. M. (2017) · Analytical Chemistry · doi:10.1021/acs.analchem.7b04621 · Cited by 12
Epigenetic and non-coding regulation of alcohol abuse and addiction
Farris, S. P., & Mayfield, R. D. (2020) · International review of neurobiology · doi:10.1016/bs.irn.2020.08.006 · Cited by 12
Nanocarrier‐delivered small interfering RNA for chemoresistant ovarian cancer therapy
Zou, M., Du, Y., Liu, R., Zheng, Z., & Xu, J. (2021) · Wiley Interdisciplinary Reviews - RNA · doi:10.1002/wrna.1648 · Cited by 12
Role of cGAS-STING pathway in fibrotic disease
Feng, L., Zhang, F., Cao, J., & Xiong, W. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107971 · Cited by 13
Enhancing lipid nanoparticles-mediated RNA delivery to glioblastoma via targeted strategies
Wang, N., Qing, Q., Xue, Y., Cai, S., Zheng, M., Zhang, D., & Ismail, M. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114472 · Cited by 14
Multifunctional aggregates for precise cellular analysis
Hu, J., Dong, X., Jiang, W., Xia, F., & Lou, X. (2021) · Science China Chemistry · doi:10.1007/s11426-021-1051-9 · Cited by 11
Targeted Nanocarrier Delivery of RNA Therapeutics to Control HIV Infection
Agbosu, E., Ledger, S., Kelleher, A. D., Wen, J., & Ahlenstiel, C. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14071352 · Cited by 13
Cytoplasmic delivery of siRNA using human-derived membrane penetration-enhancing peptide
Nakamura, M., Fujiwara, K., & Doi, N. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01667-4 · Cited by 11
Short interfering RNA in colorectal cancer: is it wise to shoot the messenger?
Kiruthiga, C., Balan, D. J., Devi, K. P., Nabavi, S. F., Reshadat, S., Khayatkashani, M., Mahmoodifar, S., Filosa, R., Amirkhalili, N., Pishvaei, S., et al. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.175699 · Cited by 11
Wang, J., Zhao, P., Chen, Z., Wang, H., Wang, Y., & Lin, Q. (2023) · Materials Today Bio · doi:10.1016/j.mtbio.2023.100632 · Cited by 11
Pang, J., Huang, L., Lian, Y., Yuan, Z., Wang, F., & Zhang, L. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.130729 · Cited by 11
RNA modifications in pulmonary diseases
Qian, W., Yang, L., Li, T., Li, W., Zhou, J., & Xie, S. (2024) · MedComm · doi:10.1002/mco2.546 · Cited by 11
Cen, B., Zhang, J., Pan, X., Xu, Z., Li, R., Chen, C., Wang, B., Li, Z., Zhang, G., Ji, A., et al. (2024) · International Journal of Nanomedicine · doi:10.2147/ijn.s483252 · Cited by 12
Polymer-siRNA nanovectors for treating lung inflammation
Goswami, R., Nagaraj, H., Çiçek, Y. A., Nasim, N., Mirza, S. S., Hassan, M. A., Mhaske, R., Saravanan, D. M., Noonan, C., Pham, E., et al. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.12.053 · Cited by 16
Nanobody-Oligonucleotide Conjugates (NucleoBodies): The Next Frontier in Oligonucleotide Therapy
Tripathy, R. K., & Pande, A. H. (2025) · Pharmaceutical Research · doi:10.1007/s11095-025-03829-z · Cited by 11
Lin, M., Hu, X., Chang, S., Chang, Y. Z., Bian, W., Hu, R., Wang, J., Zhu, Q., & Qiu, J. (2021) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2021/6678422 · Cited by 11
Kleczewska, N., Sikorski, P. J., Warminska, Z., Markiewicz, Ł., Kasprzyk, R., Baran, N., Kwapiszewska, K., Karpińska, A., Michalski, J., Hołyst, R., et al. (2021) · Chemical Science · doi:10.1039/d1sc02143e · Cited by 11
Multi-functional engineered polypeptide-based drug delivery systems for improved cancer therapy
Li, X., Liu, J., Chen, H., Chen, Y., Wang, Y., Zhang, C. Y., & Xing, X. (2022) · Green Chemical Engineering · doi:10.1016/j.gce.2022.07.010 · Cited by 11
Intracellular miRNA or siRNA delivery and function
Zhdanov, V. P. (2018) · Biosystems · doi:10.1016/j.biosystems.2018.05.007 · Cited by 11
Zhou, Y., Zang, C., Wang, H., Li, J., Cui, Z., Li, Q., Guo, F., Yan, Z., Wen, X., Xi, Z., et al. (2019) · Organic & Biomolecular Chemistry · doi:10.1039/c9ob00765b · Cited by 11
Molecular Construction of Sulfonamide Antisense Oligonucleotides
Korotkovs, V., Reichenbach, L. F., Pescheteau, C., Burley, G. A., & Liskamp, R. M. J. (2019) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.9b00941 · Cited by 11
Lv, Z., Ma, J., Wang, J., & Lu, J. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s208263 · Cited by 11
RetractedOligonucleotide-based therapies for cystic fibrosis
Kreda, S. M. (2022) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2022.102271 · Cited by 10
Hydatidiform mole: a vascular congenital anomaly.
Reynolds, S. R. M. (1976) · PubMed · Cited by 11
Gan, R., Ni, E., Li, G., & Chen, W. (2025) · MedComm – Biomaterials and Applications · doi:10.1002/mba2.70022 · Cited by 10
Long Non-coding RNA Based Therapy for Cardiovascular Disease
Quinones, N. B., Belluomo, R., Juni, R. P., & Boon, R. A. (2025) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-025-10686-z · Cited by 12
Emerging roles of microRNAs in septic cardiomyopathy
Wu, M., Li, G., Wang, W., & Ren, H. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1181372 · Cited by 10
Pacelli, C., Rossi, A., Milella, M., Colombo, T., & Pera, L. L. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914862 · Cited by 10
Hill, A. C., Becker, J. P., Slominski, D., Halloy, F., Soendergaard, C., Ravn, J., & Hall, J. (2023) · ACS Omega · doi:10.1021/acsomega.3c05144 · Cited by 11
Advantages and disadvantages of RNA therapeutics
Huy, B. L., Phuong, H. B. T., & Xuan, H. L. (2024) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2023.12.016 · Cited by 10
Devisetty, U. K., Neef, E. D., Gordon, E. R. L., Zapata, V. V., Narva, K. E., Mézin, L., Cahon, P. M., Witwer, K. W., & Sridharan, K. (2024) · Computational Toxicology · doi:10.1016/j.comtox.2024.100340 · Cited by 10
Vasukutty, A., Chahal, S., Lee, K., Park, S., Kim, S., Shin, E., Kim, Y. J., Kim, D., Lee, J., Jeong, H.-K., et al. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202403374 · Cited by 10
Sun, K., Kang, Z., Chen, Y., Yu, Y., Han, L., Shi, Y., Chen, L., Shi, J., Chen, Y., & Sun, J. (2025) · Advanced Science · doi:10.1002/advs.202412908 · Cited by 10
Gao, D., Xu, Z., Li, X., Zhao, Y., Min, Q., Chen, Z., Xu, Q., Tian, Y., Xu, J., & Zhu, J. (2025) · Angewandte Chemie International Edition · doi:10.1002/anie.202505290 · Cited by 11
Abavisani, M., Sajjadi, S. M., Ebadpour, N., Kesharwani, P., Karav, S., & Sahebkar, A. (2025) · Chemical Engineering Journal · doi:10.1016/j.cej.2025.165777 · Cited by 10
Metadata
- Authors
- Dowdy, S. F.
- Affiliations
- University of California San Diego (US)
- Corresponding author
- Dowdy, Steven F
- ORCID
- Dowdy, Steven F
- Venue
- Nature Biotechnology
- Published
- 2017-02-27
- Volume
- 35
- Issue
- 3
- Pages
- 222-229
- ISSN
- 0733-222X (ISSN-L)
- 1087-0156
- 1546-1696
- OpenAlex
- W2594133976
- Cited by
- 1,139
- References
- 105
- Citations by year
- 2026: 103 · 2025: 130 · 2024: 147 · 2023: 133 · 2022: 130 · 2021: 141 · 2020: 104 · 2019: 88 · 2018: 120 · 2017: 41
- FWCI
- 9.04
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Nature Biotechnology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA and protein synthesis mechanisms
- Keywords
- RNA therapeutics, RNA delivery, lipid bilayers, siRNA, microRNA, antisense oligonucleotides, aptamers, synthetic mRNA, CRISPR/Cas9
- MeSH terms
- RNAi Therapeutics, Animals, Cell Membrane, Humans, RNA, RNA Interference, Nanocapsules, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
